Method of treating keratoconus

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be applied for treatment of keratoconus. For this purpose ablation of epithelial layer is performed. Funnel with internal diameter, which exceeds diameter of cornea, is placed on eyeball surface. After that, funnel is filled with 0.1% solution of riboflavin on 20% solution of dextran until the volume totally covering cornea surface. When solution volume decreases, it is periodically added into funnel, supporting constant volume of solution in funnel until cornea is saturated with riboflavin solution. After that, ultraviolet irradiation of cornea with wave length 365 nm is carried out for 30 minutes. Irradiation is accompanied with additional instillations of 0.1% solution of riboflavin on 20% solution of dextran on cornea each 2-3 minutes to support its concentration.

EFFECT: method ensures acceleration of cornea saturation with riboflavin, increasing treatment efficiency, makes subjective endurance of procedure tolerance easier, is simple in implementation.

1 ex

 

The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of keratoconus.

There is a method of treatment of keratoconus (see Stronger Cross-linking in the Anterior Stroma // Abnormalities Surgery and Cross-linking, 2009, p.16-18), which consists in removing the epithelial layer of the cornea, the cornea for saturation of 0.1% solution of Riboflavin in 20% dextran solution and subsequent UV irradiation with a wavelength of 365 nm for 30 minutes, the Saturation of the cornea with Riboflavin solution carried by repeated instillation every 2-3 minutes for 30 minutes.

One of the disadvantages of this method is the difficulty of achieving a sufficient level of saturation of the cornea 0.1% Riboflavin solution by repeated instillation. In addition, the procedure is long, which is uncomfortable for patients, and insufficient saturation of the cornea with Riboflavin solution in certain moments during the procedure you can contact of the cornea with the ambient air, which causes the patient expressed corneal syndrome.

The present invention solves the problem of optimizing the treatment of keratoconus. The technical result consists in the improved conditions and to accelerate the saturation of the cornea with Riboflavin and, in General, increase effectivestrategies treatment of keratoconus. Through the use of a funnel with an inner diameter greater than the diameter of the cornea, possibly using a plastic funnel of wearechangela from a kit of apparatus for measuring intraocular pressure "Geotest-60")installed on the surface of the eyeball and fill 0.1% solution of Riboflavin in 20% dextran solution to volume, completely covering the surface of the cornea, significantly reduce the duration of the stage of saturation of the cornea with Riboflavin solution and improve the quality of its saturation. At the same time excluded contact devitalizirovannah cornea with air, which reduces the likelihood of corneal syndrome in a patient and, accordingly, facilitates subjective tolerability of the procedure being performed. The method is simple in execution and is not difficult to specialists when using it.

This technical result is achieved in that in the method of treatment of keratoconus, which consists in removing the epithelial layer of the cornea to its saturation 0.1% solution of Riboflavin in 20% dextran solution and subsequent UV irradiation with a wavelength of 365 nm for 30 min to saturate the cornea with Riboflavin solution to the surface of the eyeball set funnel with an inner diameter greater than the diameter of the cornea, after h is th funnel fill a 0.1% solution of Riboflavin in 20% dextran solution to volume, completely covering the surface of the cornea, and for reducing the volume of solution is periodically added to the funnel, maintaining a constant volume of solution in the funnel before saturation of the cornea with a solution of Riboflavin and ultraviolet irradiation of the cornea accompanied by additional instillation of 0.1% Riboflavin solution in 20% dextran solution on the cornea every 2-3 minutes to maintain his concentration.

A method of treatment of keratoconus is as follows.

Previously conducted a complete preoperative examination, including multipoint measurement of corneal thickness. Determine the thickness of the epithelial layer of the cornea. Set parameters for excimer laser ablation of the epithelial layer. In the sterile operating conditions hold excimer laser ablation of the epithelial layer on the estimated depth component not more than two thirds of the thickness of the epithelial layer of the cornea, or mechanical deepithelization corneal diameter corresponding to the area of UV irradiation. On the surface of the eyeball set funnel with an inner diameter greater than the diameter of the cornea, after which the funnel is filled with 0.1% Riboflavin solution 20% solution of dextran T 500 to volume, completely covering the surface of the cornea. For reducing the volume of the solution, its period, which if added to the funnel, maintaining a constant volume of solution in the funnel before saturation of the cornea with Riboflavin solution. Biomicroscopic control the saturation of the cornea with a solution of Riboflavin spend 15 minutes after the start of the procedure. Enough about the level of saturation of the cornea with Riboflavin solution says diffuse yellow staining of the stroma of the cornea. After saturation of the cornea with Riboflavin solution carry out ultraviolet irradiation of the cornea with a wavelength of 365 nm for 30 min, which is accompanied by further instillations of 0.1% solution of Riboflavin in 20% dextran solution on the cornea every 2-3 minutes to maintain his concentration. Each control of the thickness of the cornea carry out the following steps of operation: before deepithelization and after its completion, and after saturation of the cornea with Riboflavin solution and after the ultraviolet irradiation of the cornea. The duration of treatment in our proposed method on average is 40-45 min, which is less than in the known methods.

Clinical example of implementation of the proposed method.

Patient A., 32 years. Complaints about progressive decreased vision in the left eye (OS). Optical correction means the patient does not use. There was a full ophthalmologic examination, including visiometry, refractometry in Oba the circumstances and conditions cycloplegia, multipoint pachymetry, measurement of corneal diameter, the determination of the density of endothelial cells of the cornea, keratotopografii, fundus examination with a lens Goldman.

The results of the survey: VOD=1,0, ROD=sph-of 0.25 Diopters cyl to 0.5 Diopters, a×10, VOS=0,1 cyl to 6.0 Diopters (a×130=0,3, ROS=sph is 1.75 Diopters cyl-9,0 Diopters a×137, pachymetry in the Central optical zone OD=481 μm, pachymetry in the Central optical zone OS=422 microns. The density of endothelial cells OD=2902 CD/mm2the density of endothelial cells OS=2750 CD/mm2the corneal diameter OD=10.5 mm, OS=11,0 mm Keratotopografii on OS picture of keratoconus.

Clinical Ds "Keratoconus OS II degree. The patient completed the treatment of keratoconus OS on the proposed method. First, under installazioni local anesthesia performed ablation by excimer laser installation the Schwind Amaris epithelial layer of the cornea at a depth of 20 μm, which is no more than two-thirds of the thickness of the epithelial layer of the cornea. The diameter of the zone of ablation amounted to 8.0 mm. Control thickness measurement of the cornea after laser ablation - 402 μm. To saturate the cornea 0.1% solution of Riboflavin in 20% solution of dextran T 500 on the surface of the eyeball was installed funnel that comes with the device for measuring intraocular pressure "Geotest-60" plastic funnel of wearechangela with internal dia is slow, greater than the diameter of the cornea. The funnel was filled with a 0.1% solution of Riboflavin to volume of 1.0 ml, completely covering the surface of the cornea. The required level of saturation of the cornea with Riboflavin was achieved already after 15 minutes after the start of the stage. Additional instillation of Riboflavin solution in the funnel to maintain its volume was not required. In the process of saturation of the patient had no complaints. As a result after saturation of the cornea immediately before UV irradiation for each control the thickness of the cornea was 405 μm. Held ultraviolet irradiation of the cornea with a wavelength of 365 nm, with a capacity of 3.0 mW/cm2 from a distance of 50 mm for 30 min with additional installations of 0.1% solution of Riboflavin in 20% dextran solution on the cornea every 2-3 minutes to maintain the concentration of Riboflavin corneal Thickness after exposure amounted to 415 μm. After completion of treatment to the patient in the operated eye appointed Tobrex 1 drop 6 times a day, Corneregel 1 drop 3-4 times per day. Complete epithelialization was achieved in 42 hours after surgery. On the 10th day after the operation VOS=0.3 s cyl-6,0 a×130=0,6-0,8.

A method of treatment of keratoconus, which consists in removing the epithelial layer of the cornea to its saturation of 0.1%Riboflavin solution at 20 Mr. dextran solution the subsequent UV irradiation with a wavelength of 365 nm for 30 min, characterized in that the saturation of the cornea with Riboflavin solution to the surface of the eyeball set funnel with an inner diameter greater than the diameter of the cornea, after which the funnel is filled with 0.1%Riboflavin solution at 20 Mr. dextran solution to volume, completely covering the surface of the cornea, and for reducing the volume of solution is periodically added to the funnel, maintaining a constant volume of solution in the funnel before saturation of the cornea with a solution of Riboflavin and ultraviolet irradiation of the cornea accompanied by further instillations of 0.1-aqueous solution of Riboflavin 20 Mr. dextran solution on the cornea every 2-3 min to maintain his concentration.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology and can be used for treatment of diabetic diffuse macular edema. For this purpose 0.5 ml of 1% dexason solution and 0.5 ml of emoxipin are successively introduced in injection into parabulbar space and magnetic stimulation of optic analyser is performed. Magnetic stimulation is performed by pulse alternating magnetic field with growing strength within 6-12 mT with 50 Hz frequency and 10 min duration. Course of treatment constitutes 10 sessions.

EFFECT: method ensures efficient non-traumatic treatment of the last stage of proliferative diabetic retinopathy.

24 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to ophthalmology, and may be used to treat recurrent haemophthalmia in diabetic retinopathy. That is ensured by permanent administration of Endotelon 150 mg, Tranexam 500 mg, Dicynone 250 mg 2 times a day. They are added by Angiovit 1 tablet a day for 1 month, 3 times a year.

EFFECT: method enables providing the long-term remission and stabilisation of a visual function ensured by the complex effect on the morphofunctional changes of the endothelium and vascular-thrombocyte haemostatic disorders.

1 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of ophthalmology. Ophthalmological medication in form of eye drops, contains 0.2-0.5 wt % of disulfiram, dissolved in pharmaceutically acceptable water-based carrier, 0.5-2.0 wt % of hydroxypropyl cyclodextrin, 2.0-5.0 wt % of taurine; agent, which ensures required resin condition, containing sodium chloride, sodium monohydrophosphate and dihydrophosphate, and methylparaben (nipagin) as a preservative.

EFFECT: invention ensures effective treatment of pathological conditions of eyes, such as cataract, glaucoma, ophthalmological hypertension and traumatic injuries of cornea, extends arsenal of existing preparations in form of eye drops.

6 cl, 5 tbl, 2 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be applied for treatment of "dry" form of age-related macular degeneration. Three-component complex, which contains mesenchymal stem cells, labelled with magnetic micro particles, is introduced to patient extrasclerally in macular zone projection. Cells in this complex are transposed into biological or synthetic fine-pore material. This material is fast connected with polymeric magnetic material with induction of permanent magnetic field 1.5 mT, with multipolar reversible magnetisation.

EFFECT: invention ensures improvement or stabilisation of visual functions due to directed delivery of cells to pathologic focus and holding cells in focus for the time, necessary for obtaining therapeutic effect.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pyrrol derivatives of formula (1): or a pharmaceutically acceptable salt thereof wherein the values A, R1-R3, n are specified in clause 1 of the patent claim.

EFFECT: compounds (1) inhibit activity against the interleukin IL-6 production that allows using them both in pharmaceutical compositions, and in a prophylactic drug for ocular inflammatory disease.

23 cl, 2 tbl, 22 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to ophthalmology. The group of inventions refers to pharmacological action of a compound functioning as a PPARr agonist on the corneal epithelial barrier function. The PPARr agonist, such as rivoglitazone, DRF-2593, GW-544 and BMS-298585, perfectly enhances the corneal epithelial barrier function in the study of enhancing the corneal epithelial barrier function, and therefore it is useful as a preventive agent or therapeutic agent for an ocular infection or eye complaints of unknown aetiology caused by the decreased corneal epithelial barrier function.

EFFECT: group of inventions provides enhancing the corneal epithelial barrier function in the patients with diabetes, age-related decrease in the corneal epithelial barrier function, and patients underwent refractive surgery, such as PRK (photorefractive keratectomy) and LASIK (laser keratomileusis in situ), and cataract surgery.

12 cl, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used for inducing posterior detachment of vitreous body. For this purpose 0.1 ml of miniplasmin solution is introduced endovitreally in 4 mm from limb. Preliminarily before introduction, solution of buffer salts up to pH values of 6.8-8.0 with osmolarity 280-320 mOsm to concentration of miniplasmin in solution 1 mg/ml is added into miniplasmin, mixed, heated to temperature 37°C and kept at said temperature for from 5 to 15 minutes.

EFFECT: method ensures reduction of toxic impact on retina and vitreous body, improvement of proteolytic properties of miniplasmin and, therefore, more complete detachment of vitreous body with reduction of interference trauma.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to immunology. There are studied: a method of decreasing the load and of reducing the number of plaques in the layer of retinal ganglion cells, of reducing the total amount of soluble amyloid-beta in the layer of retinal ganglion cells and of maintaining or reducing intraocular pressure in a subject, as well as a method of preventing, treating and relieving the symptoms of ophthalmic diseases associated with amyloid-beta related pathological disorders or changes in tissues of the visual system, a diagnostic technique for such disease and predisposition thereto, and a method of monitoring the minimal residual ophthalmic disease associated with the amyloid-beta related pathological disorders or changes, involving administering the composition containing the anti-amyloid-beta antibody to the patient. The present invention can find further application in a therapy of the ophthalmic diseases.

EFFECT: what is presented is a pharmaceutical composition for treating the ophthalmic diseases containing the anti-amyloid-beta antibodies.

31 cl, 3 ex, 13 tbl, 20 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to ophthalmology. A method for increasing the stability of a prostaglandin composition comprising prostaglandin, a preserving agent and pharmaceutically acceptable excipients, wherein the method comprises a stage whereat: the prostaglandin composition specified in a group consisting of Travoprost, Latanoprost, Bimatoprost and Tafluprost is packaged in a reusable low-density polyethylene container made of a low-density polyethylene wherein said low-density polyethylene container represents a low-density polyethylene bottle prepared with the use of blow-fill-seal technology, wherein low-density polyethylene resin is specified in a group consisting of Purell PE 1810 E, Purell PE 1840 H, Purell PE 3020 D, Purell PE 3040 D, Purell PE 3220 D.

EFFECT: group of inventions provides the local reusable ocular administration, the stability of the composition at room temperature up to 25°C for more than twelve months.

18 cl, 5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of medicine, in particular to ophthalmology. Medicinal compositions for intravitreal injections and methods of treating ophthalmological disorders are disclosed. Medicinal compositions represent suspensions on the basis of low-soluble medication, such as triamcinolone acetonide. Compositions of suspensions have relatively low viscosity and are easily extracted via needle of 27- or 30-gauge needle, but are highly flocculated and can be easily redispersed.

EFFECT: group of inventions ensures improvement of vitreos body visualisation in the course of vitrectomy, treatment of ophthalmological disorders.

20 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and may be used for the purpose of prevention of recurrent malignant pelvic tumours or non-organic retroperitoneal tumours following the surgical management. A photosensitiser having high tropism to pelvic and retroperitoneal tumour tissues is administered intravenously. A completely extracted tumour bed is exposed to a photodynamic effect within healthy tissues using a light source of wave length characteristic of the photosensitiser used. It is combined with simulating an exposure field by placing a moistened surgical drape in a surgical wound. The laser exposure is generated by using a macrolens from at least one position. An irradiation energy dose makes 840 J to 1710 J.

EFFECT: method enables improving the effectiveness of photodynamic therapy ensured by using the photosensitisers with high tropism to pelvic and retroperitoneal tumour tissues and a possibility to increase a dose of laser light through generating the exposure field and determining its clear limits.

3 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and may be used to treat a benign growth of cavernous hemangioma of the upper airways. The new growth is extracted in a coagulation mode by Nd:YAG laser exposure at wave length 1.064 nm. A quartz light guide of the diameter of 400 mcm is used. The output laser power is 15 Wt. The exposure time is 6 to 10 minutes. The distance of the light guide end to the tumour is 3 to 10 mm. The power density is 850 to 50 Wt/cm2. The pulse length is 0.5 to 1 s.

EFFECT: method enables achieving deep coagulation of cavernous vascular tissue without causing thermal damage to the mucous membrane covering the hemangioma followed by sclerosing of the cavernous component of the hemangioma tissue and replacing it by scar tissue due to thermal ablation of the abnormal blood vessels.

2 ex

FIELD: medicine.

SUBSTANCE: method refers to medicine, and may be used for treating pathologies of the near-surface skin, and particularly for low-intensity laser and photodynamic therapy. A depth of the pathological derma is determined. If the depth is less than 0.22 mm, the region is exposed to light beam at wave length 418±5 nm. At the depth within the range of 0.22 mm to 0.9 mm, the region is exposed at wave length 575±5 nm. The depth within the range of 0.9 mm to 2.5 mm enables the exposure at wave length 585±5 nm. The depth within the range of 0.9 mm to 2.5 mm requires the region to be exposed at wave length 600±5 nm.

EFFECT: method enables increasing a number of the formed oxygen molecules formed in the skin derma at the different depths in the derma due to blood oxyhaemoglobin dissociation under the influence of light of a certain spectral composition.

2 dwg

FIELD: medicine.

SUBSTANCE: method refers to medicine, and may be used for treating pathologies of the near-surface skin, and particularly for low-intensity laser and photodynamic therapy. The skin surface is exposed to a light beam at wavelength 575 nm, spectral half-width no more than 5 nm.

EFFECT: method enables reinforcing molecular oxygen in skin derma due to blood oxyhaemoglobin dissociation under the influence of light of the given spectral composition.

2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to surgery, physiotherapy. The method involves application of a dressing, the magnetic therapy, and the laser therapy. The application of the dressing is preceded by the 6-minute wound exposure to laser light generated by UFL-01 apparatus at wave length 0.63 mcm; the therapeutic course is 7 sessions. The application of the wound dressing is followed by the 20-minute exposure. The exposure involves the magnetic field of induction 100% generated by Alimp-1 apparatus. The exposure frequency is 20 Hz. The therapeutic course consists of 10 sessions.

EFFECT: method provides reduced length of treatment.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely to phototherapeutic apparatuses for newborns. A first embodiment of the apparatus comprises a body assembly having a connection site, a light source, a lock switch for locking and unlocking an operating status of the light source, a positional light mode adapter selectively detachably connected to the body assembly at the connection site. The attachment of the adapter to the connection site switches the lock switch from the blocking configuration in the unlocking configuration; the disconnection of the adapter switches the lock switch. A panel lighting mode assembly comprises a lighting panel mode adapter detachably connected to the body assembly at the connection site, and a light guide connected to a light-emitting panel. In the second version, there is a LED-assembly in the blue range of the visible spectrum inside the body assembly between its opposite ends to emit light from one end of the body assembly. The body assembly has a central portion of a smaller diameter and the connection site in the centre of an end element with a hole to accommodate a detachably connected positional light mode adapter or the panel lighting mode adapter. In the third version, a circuit board is connected to the LED-assembly. The opposite ends of the body assembly comprise the inlet and outlet air tubes, a fan to circulate the air in the longitudinal direction through the inlet, intermediate and outlet tubes. In the fourth version, the panel lighting mode assembly further comprises an elongated flexible light guide and light-emitting panel, and a suspension construct for suspending the body assembly, wherein when the lighting panel mode adapter is disconnected from the body assembly, and the positional light mode adapter is disconnected from the body assembly, no light is emitted from the body.

EFFECT: use of the invention allows extending the range of the phototherapeutic apparatuses.

23 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly physiotherapy, and may be used for treating diabetic polyneuropathy. What is involved is a phototherapy by Bioptron-compakt III apparatus. A lamp is placed at 5 cm from an abdominal wall surface above a projection of a pancreas. A light beam containing different wave lengths within the range of 400 nm to 34000 nm are used. The power flow density is 40 mWt/cm2, the optical energy flow density is 2.4 J/cm2, the length is 4 minutes. Then, the lamp is placed at 5 cm from a surface of a back above spines on a projection of the segments T7-T9 pravertebrally from both sides for 2 min from each side. Thereafter, the lamp is placed at popliteal spaces at 5 cm to be exposed in turn for 2 min on each side. A total length of one procedure is 12 minutes, daily; the therapeutic course is 10 procedures. On the same day, an electrophoresis session is conducted through a temporary spacer with 1% placenta hydrolysate by means of Potok-1 apparatus. The current intensity is 10-15 mA, the length is 20 min. The electrodes are placed as follows: a Y-electrode (+), each of 160 cm2 is placed paravertebrally in an interscapular region at a small distance from each other, a Y-electrode (-), each of 150 cm2 is placed on gastrocnemius muscles. The therapeutic course comprises 10 daily procedures.

EFFECT: method enables recovering all the types of sensitivity within lower extremities, the functional state of the pancreas and the carbohydrate and fat metabolic processes ensured by anti-inflammatory, anti-oedema and adaptive effects.

5 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and may be used for treating the children with severe thermal injuries. There are involved the detoxification and anticoagulant therapy to create the programmable anticoagulation conditions. It is followed by a procedure of intravenous laser blood irradiation at wave length 0.63 mcm and light guide output power 2.5 mW. The first procedure of intravenous laser blood irradiation is performed for 10 minutes, with the first 5 min - at 100 Hz, and the next 5 minutes - at a frequency of 1500 Hz. Further, the procedure of intravenous laser blood irradiation is performed for 14 min, each of 7 min at frequencies of 100 Hz and 1500 Hz. The sessions of intravenous laser blood irradiation are performed every 12 hours for 5-7 days.

EFFECT: method enables reducing the level of endogenous intoxication, improving the oxygen-transport blood function, accelerating the repair processes in burn wounds and reducing the area of plastics interventions by optimising the therapy.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and may be used for treating dystrophic diseases of the vulva by photodynamic therapy. That is ensured by intravenous administration of Photoditazine 0.8-1.0 mg/kg, and 90-120 minutes later, it is followed by the unanesthetised light exposure on the area of the vulva in a continuous mode by a LED apparatus at wave length 660 nm. A dose of the supplied light energy is 180-250 J/cm2 for a total length of light exposure of 30-50 minutes. If the clinical symptoms of the disease appear to be persistent, the photodynamic therapy is repeated to achieve a positive therapeutic effect. With a large area of abnormality, the vulva area is divided into quadrants that are consistently exposed to light.

EFFECT: method provides a highly effective minimally invasive, organ preservation method of treating dystrophic diseases of the vulva, which provides a complete recovery of the disease; it is not accompanied by side effects, enables reducing the length of treatment, ensuring the treatment in an outpatient setting.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to paediatrics. The exposure is generated by Bioproton apparatus radiating incoherent polarised light. On the first day, the reflex areas are exposed to red light, namely, finger tips, feet, ears for 5 seconds at a distance of 10 cm. On the second day following the similar exposure on the reflex zones, the eyes are exposed to blue, purple and green for 2 -3 seconds. On the third day, after the similar exposure on the reflex zones, the eyes are exposed to blue, yellow, green, blue, orange, red and purple for 2-3 seconds. In depression syndrome, the session is ended by the exposure to red, and in excitation syndrome - to purple. The eyes are exposed at a distance of 5 cm from the eyes. The therapeutic course is 5-15 daily procedures.

EFFECT: method extends the range of products for CNS stimulation in newborns and infants.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present group of inventions refers to medicine, namely therapy and endocrinology, and concerns treating metabolic syndrome and diabetes. That is ensured by administering an effective amount of a composition comprising an activator of adenosine-5'-monophosphate-activated protein kinase (AMPK), and an anti-inflammatory agent having serotonergic activity.

EFFECT: administering the given composition provides the effective treatment of metabolic syndrome and diabetes by improving lipid metabolism due to inducing the enhanced oxidation of fatty acids by the ingredients of the composition.

29 cl, 4 ex

Up!